Skip to main content

Synthesis of Thieno[2,3-d]oxazines and Thieno[2,3-d]thiazines as Subtype Specific Kainate Receptor Antagonists

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

For the development of new antiepileptics the kainate receptors, GluR6 and GluR5, are important targets. Based on the anticonvulsant effects of chinazolines and thieno[2,3-d]pyrimidines that are known from the literature, thieno[2,3-d][1.3]oxazines were synthesized and studied for their inhibitory properties at GluR6 and GluR5 receptors. The strongest inhibitor activity was observed with 5-methyl-6-phenyl-thieno[2,3-d][1.3]oxazines with C1 or C3-substituents in position 2 (3b-f). The 2-trihalide-methyl-substituted compounds 3c and 3d were the most active inhibitors at the GluR5- receptor (IC50=23.4 μmol, 16 μl). The 2-isopropyl-substituted compound 3f displayed the strongest activity at the GluR6- receptor (IC50=8.7 μmol). A number of thieno[2,3-d][1.3]thiazines and thieno[2,3-d]pyrimidines that were synthesized from the thieno[2,3][1.3]oxazines did not show any activity.

Keywords: Glutamate receptor antagonists; anticonvulsives; kainate receptor antagonists; thieno[2,3-d]-pyrimidines; thieno[2,3-d][1.3]oxazines; thieno[2,3-d][1.3]thiazines

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986709789878283

Affiliations: Institute of Pharmacy, Faculty of Biosciences, Pharmacy and Psychology, University of Leipzig, Bruderstra├če 34, 04103 Leipzig, Germany.

Publication date: December 1, 2009

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2009/00000016/00000035/art00008
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more